📌 Key Takeaways
- Topic: Silica Surface Area Explained: Typical BET Values by Type and Why It Matters
- Keywords: silica filler for CCL
- Published: 2026-11-20 14:22:31
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Silica for Feed Carrier: How It Carries Vitamins and Liquids in Animal Feed
- Spherical Silica for Semiconductor Packaging: Key Specs, Purity and Selection Guide
- Wollastonite vs Silica: Filler Performance and Applications Compared
- Chemotherapy and radiotherapy
- Fumed Silica 380 m²/g: Properties, Thickening Performance and Applications
- Liu, Y. et al. Dual-functionalized janus mesoporous silica nanoparticles with active targeting and charge reversal for synergistic tumor-targeting therapy. ACS Appl. Mater. Interfac. 11, 44582-44592 (2019). Post CAS Google Scholar
- 325 Mesh Silica: Particle Size, Specifications and Common Applications
Wood Coating Matting Agent: How to Achieve a Low-Gloss, Clear Finish
What is silica (SiO₂)?
silica supplier Thailand
What is the difference between fumed silica and precipitated silica?
What drives silica raw material prices?
spherical silica for semiconductor packaging Although a lot of reviews have already reported on the progress of MSNs in the biomedical field (Fig. 1b ), the scope of this review supplies a more comprehensive summary over the past decades from different aspects. Throughout this review, we deliver an overview of the development history of MSNs in the biomedical field, introduce some key research advances, and summarize the diverse types of MSNs. We then summarize the nanocomposites composed of different functional inorganic factors (i.e., metal compound NPs, noble metal NPs, upconversion NPs, and metal-free NPs) with MSNs. Our review focuses on the objectives of surface functionalization of MSNs, which contain improving biocompatibility, improving targeting, and enabling precise drug delivery processes. We also highlight recent advances in MSNs-based biomedical applications, with particular stress on diverse types of targeted therapeutic plans. Lastly, we discuss the clinical translational status of MSNs and the current difficulties they face in the biomedical field.
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.